Stocktoria
Acurx Pharmaceuticals, Inc. ACXP
Acurx Pharmaceuticals, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| R&D expense | $1.8M | $5.4M | $6.0M | $4.8M | $2.0M | $2.2M |
| SG&A expense | — | — | — | — | $208,270 | — |
| Operating income | -$8.1M | -$14.1M | — | — | — | — |
| Income tax | — | — | — | $0 | — | $0 |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M | -$4.6M |
| EPS (diluted) | $-5.32 | $-17.45 | $-1.15 | $-1.12 | $-1.49 | $-0.74 |
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M | -$3.4M |
| Cash & equivalents | — | — | — | — | — | $3.2M |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M | $3.2M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843,909 | $522,434 |
| Shareholders' equity | $5.3M | $615,121 | $4.7M | $7.3M | $12.4M | $2.7M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.